Schroder Investment Management Group Sells 24,112 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Schroder Investment Management Group reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 50.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,230 shares of the biopharmaceutical company’s stock after selling 24,112 shares during the period. Schroder Investment Management Group’s holdings in Alnylam Pharmaceuticals were worth $5,483,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $1,045,822,000. Norges Bank bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $577,941,000. Raymond James Financial Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $61,160,000. Finally, Proficio Capital Partners LLC grew its holdings in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after acquiring an additional 192,916 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 10.1 %

Shares of NASDAQ:ALNY opened at $235.74 on Friday. The stock’s fifty day simple moving average is $259.03 and its 200-day simple moving average is $260.33. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders sold 71,234 shares of company stock worth $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ALNY. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Finally, StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.